PDE-5 Inhibitors for BPH-Associated LUTS

Author(s): Philip Brousil, Majid Shabbir, E. Zacharakis, Arun Sahai

Journal Name: Current Drug Targets

Volume 16 , Issue 11 , 2015

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH-LUTS) are a highly prevalent problem, and with considerable burden to quality of life. Evidence has emerged that a strong correlation exists in men suffering both BPH-LUTS and erectile dysfunction (ED). Phosphodiesterase type 5 inhibitors (PDE5i) have been shown to be highly effective in treating ED and more recently there is evidence that men with LUTS also benefit. In this review article we discuss the common pathogenic pathways of ED and LUTS, the scientific basis of PDE5i use, the efficacy of PDE5i in LUTS either as monotherapy or in combination with other established medications used in LUTS.

Keywords: Benign prostatic hyperplasia, LUTS, PDE5 inhibitors, erectile dysfunction.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [1180 - 1186]
Pages: 7
DOI: 10.2174/138945011611151013164756
Price: $65

Article Metrics

PDF: 25